top of page
Scenario of Bladder Cancer Treatment with BCG
There is a worldwide shortage of BCG-derived products with a large unmet demand
Demand
450 thousand
cases per year
worldwide
10 thousand
cases per year
reported in Brazil
70%
of cases:
BCG recommended
Opportunity
30%
relapse of treatment
with Onco BCG
3 million
doses is the estimated
world demand
U$ 450 million
is the estimated value
of the world market
BCG recombinante
A new recombinant
BCG for bladder cancer treatment
Improved treatment
The Onco rBCG has genetic modifications that increases the immune response and reduces the tumors.
Normal bladder
Bladder with tumor
Bladder with tumor treated with Onco BCG
Bladder with tumor treated with recombinant BCG
Exceptional results
Experimental results demonstrate significant improvement in antitumor properties
46% of subjects cured with Recombinant Onco BCG
against 0% among those treated with Onco BCG
bottom of page